HEPARIN PROVIDES LONG TIME SURVIVAL FOR CIRCUITS IN THE NEONATAL AND INFANT CONTINUOUS RENAL REPLACEMENT THERAPY
MIHAELA BIZUBAC 1, CĂTĂLIN CIRSTOVEANU 1,4*, DOINA-ANCA PLEȘCA 4,5, CRISTINA MUSTEA 1, ANA-MARIA DAVIȚOIU 4,5, CRISTINA FILIP 3, ALIN NICOLESCU 3, RADU SPĂTARU 2,4
1.“M. S. Curie” Children’s Hospital, Neonatal Intensive Care Unit, Bucharest, Romania
2.“M. S. Curie” Children’s Hospital, Paediatric Surgery, Bucharest, Romania
3.“M. S. Curie” Children’s Hospital, Paediatric Cardiology, Bucharest, Romania
4.“Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania
5.“Victor Gomoiu” Children’s Hospital, Paediatrics, Bucharest, Romania
Download Full Article PDF
The neonatal and infant continuous renal replacement therapy (CRRT) allows proper nutrition and medication and avoids complications such as fluid overload and hydro-electrolytic imbalances. One of the major factors on which CRRT success depends is anticoagulation. There are several options for anticoagulation and one of the first used is systemically administered heparin. We conducted a retrospective, observational, descriptive study between January 2015 and August 2020 among patients with hemodiafiltration admitted in the Neonatal Intensive Care Unit (NICU) – “M. S. Curie” Children’s Hospital, Bucharest, Romania. A group of 25 patients of CRRT-CVVHDF (continuous venous-venous hemodiafiltration) were analysed, for which the duration of administration was longer than 6 hours. We evaluated the life of the circuit, the total duration of CRRT, coagulation, haemoglobin values, platelets count, the need for substitution therapy and the adverse effects of heparin. Recently there are studies that recommend other ways of anticoagulation in neonatal CRRT as a first intention, but the successful use of heparin is still motivated due to the very long lifespan of the circuit compared to previous studies, without major complications related to anticoagulation.
